A Phase 1/2 Study of SCH727965 in Patients With Malignant Melanoma

Trial Profile

A Phase 1/2 Study of SCH727965 in Patients With Malignant Melanoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Dinaciclib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 22 Jun 2016 Status changed from active, no longer recruiting to discontinued.
    • 21 Feb 2013 Planned end date changed from 1 Aug 2010 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 21 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top